Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood RI Lynavoy Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Lynavoy Coverage for Cholestatic Pruritus in Primary Biliary Cholangitis

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicaid coverage and prior authorization for Lynavoy (linerixibat) for adult members with cholestatic pruritus associated with primary biliary cholangitis. Coverage requires applicable initial or continuation criteria, clinical documentation, specialist involvement, safety exclusions, and quantity limits.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyLynavoy Coverage for Cholestatic Pruritus in Primary Biliary Cholangitis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming eligibility, PBC diagnosis, prior treatment response, baseline ALP, and applicable Livdelzi requirements before requesting Lynavoy coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsAuthorization period
    18+ yearsMinimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 of 3PBC diagnostic criteria
    2/dayQuantity limit
    1Covered indication
    Not coveredOther indications

    Coverage Criteria

    Initial Therapy

    Covered when all of the following criteria are met for an initial 6-month authorization:

    ALL of the following

    • Member is 18 years of age or older.
    • At least TWO of the following confirm a diagnosis of primary biliary cholangitis (PBC):

      • Biochemical evidence of cholestasis with elevation of alkaline phosphatase (ALP) level for at least 6 months duration.
      • Presence of antimitochondrial antibodies (AMA) (titer >1:40 by immunofluorescence or immunoenzymatic reactivity) or PBC-specific antinuclear antibodies (ANA), such as anti-gp210 or anti-sp100.
      • Histologic evidence of PBC on liver biopsy, such as non-suppurative inflammation and destruction of interlobular and septal bile ducts.
    • Lynavoy is prescribed by or in consultation with a hepatologist or gastroenterologist.
    • Member has been evaluated for any other concomitant liver disease, such as chronic viral hepatitis, alcoholic liver disease, or liver cancer.
    • Member has moderate to severe pruritus associated with PBC that impacts daily life and sleep.
    • Documentation shows an inadequate treatment response to at least ONE of the following; contraindications, adverse effects, and/or intolerance must be documented when applicable:

      • Cholestyramine or colestipol 4 g/dose up to 16 g/day.
      • Naltrexone 50 mg daily.
      • Rifampin 150 mg to 300 mg twice daily.
      • Sertraline 75 mg to 100 mg once daily.
    • Documentation of the member's serum ALP level prior to initiation of Lynavoy.
    • If the member has a documented elevated serum ALP level, documentation shows an inadequate treatment response to Livdelzi; contraindications, adverse effects, and/or intolerance must be documented.
    • If Lynavoy is requested in combination with Iqirvo (elafibranor) or Livdelzi (seladelpar) to treat PBC, the member has a documented inadequate response, intolerance, or contraindication to Livdelzi monotherapy for PBC and PBC-associated cholestatic pruritus.

    Continuation Therapy

    Covered when all of the following criteria are met for a continuation 6-month authorization:

    ALL of the following

    • If the member has not been approved for Lynavoy by Neighborhood Health Plan of Rhode Island in the past, the clinician submits documentation that the initial therapy criteria are met.
    • Documentation shows the member has achieved or maintained a clinical benefit from Lynavoy, such as improvement in pruritus.
    • Lynavoy is prescribed by or in consultation with a hepatologist or gastroenterologist.
    • If Lynavoy is requested in combination with Iqirvo (elafibranor) or Livdelzi (seladelpar) to treat PBC, the member has a documented inadequate response, intolerance, or contraindication to Livdelzi monotherapy for PBC and PBC-associated cholestatic pruritus.

    Lynavoy must not be used in patients with decompensated cirrhosis or those with prior or active hepatic decompensated events, including variceal hemorrhage, ascites, or hepatic encephalopathy.

    type

    Lynavoy must not be used concomitantly with another ileal bile acid transporter (IBAT) inhibitor, including Bylvay (odevixibat) or Livmarli (maralixibat).

    Indications for Lynavoy other than treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients are considered experimental or investigational and are not medically necessary.

    Clinical and Quantity Parameters

    Alkaline phosphatase duration
    ThresholdElevated alkaline phosphatase (ALP) level
    Required durationAt least 6 months
    Documentation contextBiochemical evidence of cholestasis supporting PBC diagnosis
    Antimitochondrial antibody titer
    AntibodyAntimitochondrial antibodies (AMA)
    Required titer>1:40
    Testing methodBy immunofluorescence or immunoenzymatic reactivity

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization — 6 Months

    Prior authorization is required. Initial authorization may be granted for 6 months when all applicable coverage criteria are met and the member has no exclusions to the prescribed therapy.

    • Lynavoy is covered for adult PBC-associated cholestatic pruritus when the member meets the initial authorization criteria.
    • The medication must be prescribed by or in consultation with a hepatologist or gastroenterologist.
    • The member must not have decompensated cirrhosis or prior or active hepatic decompensated events, including variceal hemorrhage, ascites, or hepatic encephalopathy.
    • The member must have been evaluated for other concomitant liver disease, such as chronic viral hepatitis, alcoholic liver disease, or liver cancer.
    Prior Authorization

    Continuation Authorization — 6 Months

    Continuation authorization may be granted for 6 months when ongoing clinical benefit is documented and all applicable continuation criteria remain satisfied.

    Clinical Background

    Lynavoy (linerixibat) is covered for the treatment of cholestatic pruritus associated with PBC in adults. PBC must be confirmed by documentation of at least two specified diagnostic criteria, with management involving a hepatologist or gastroenterologist and evaluation for other concomitant liver disease.

    Initial Lynavoy Authorization

    Initial Lynavoy Authorization

    Initial authorization of 6 months may be granted when all of the following criteria are met.

    Initial Lynavoy authorization

    • Eligibility and diagnosis

      • Member is 18 years of age or older.
      • PBC confirmation — at least 2 of 3

        • Biochemical evidence of cholestasis with elevation of alkaline phosphatase (ALP) for at least 6 months duration.Elevated ALP for at least 6 months
        • Presence of antimitochondrial antibodies (AMA) with a titer greater than 1:40 by immunofluorescence or immunoenzymatic reactivity, or PBC-specific antinuclear antibodies such as anti-gp210 or anti-sp100.

    Lynavoy Continuation

    Lynavoy Continuation

    Continuation authorization of 6 months may be granted when all of the following criteria are met.

    Lynavoy continuation

    • Prior Neighborhood approval

      • If the member has not previously been approved for Lynavoy by Neighborhood, the clinician submits documentation that the initial criteria are met.
    • Clinical benefit, specialist care, and safety

      • The member has achieved or maintained clinical benefit from Lynavoy, such as improvement in pruritus.
      • The medication is prescribed by or in consultation with a hepatologist or gastroenterologist.

    Required Treatment Sequencing

    StepRequirementWhat must be documented
    1Trial of one of the following: cholestyramine or colestipol; naltrexone; rifampin; or sertraline.Inadequate treatment response. Any contraindication, adverse effect, or intolerance must also be documented.
    StepRequirementWhat must be documented
    2Livdelzi monotherapy before combination use with Iqirvo or Livdelzi, and when the member has an elevated serum ALP level.Inadequate response, intolerance, or contraindication to Livdelzi monotherapy. For elevated serum ALP, document inadequate treatment response to Livdelzi, including any contraindication, adverse effect, or intolerance.

    Lynavoy Quantity Limit

    Lynavoy 40 mg tablets
    Drug and strengthLynavoy 40 mg tablets
    Daily limit2 tablets per day
    Quantity-limit unitTablet
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyLynavoy Coverage for Cholestatic Pruritus in Primary Biliary Cholangitis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming eligibility, PBC diagnosis, prior treatment response, baseline ALP, and applicable Livdelzi requirements before requesting Lynavoy coverage.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Quantity ParametersAuthorization and Documentation RequirementsClinical BackgroundInitial Lynavoy AuthorizationLynavoy ContinuationRequired Treatment SequencingLynavoy Quantity Limit
    Lynavoy quantity limit
    MedicationLynavoy 40 mg tablets
    Quantity limit2 tablets
    FrequencyPer day
  1. Document that the member has achieved or maintained clinical benefit from Lynavoy, such as improvement in pruritus.
  2. If Neighborhood has not previously approved Lynavoy, submit documentation that the initial authorization criteria are met.
  3. The medication must continue to be prescribed by or in consultation with a hepatologist or gastroenterologist.
  4. The member must not have developed decompensated cirrhosis or experienced a hepatic decompensated event.
  5. Step Therapy

    Required Prior Antipruritic Therapy

    Before initial approval, document an inadequate treatment response to at least one qualifying antipruritic therapy. Contraindication, adverse effect, or intolerance may qualify when documented.

    • Cholestyramine or colestipol 4 g per dose, up to 16 g/day
    • Naltrexone 50 mg daily
    • Rifampin 150 mg to 300 mg twice daily
    • Sertraline 75 mg to 100 mg once daily
    Step Therapy

    Livdelzi Sequencing Requirement

    For members with an elevated serum ALP level, document an inadequate response to Livdelzi before initial approval. Contraindication, adverse effect, or intolerance to Livdelzi must be documented when applicable.

    • Submit the member's pre-initiation serum ALP documentation.
    • This sequencing requirement applies when serum ALP is elevated.
    Documentation Required

    Diagnosis and Symptom Documentation

    Submit documentation establishing that the member is an adult with PBC-associated cholestatic pruritus and that the PBC diagnosis meets the policy criteria.

    • Member is 18 years of age or older.
    • Moderate to severe pruritus associated with PBC impacts daily life and sleep.
    • PBC is confirmed by at least two of the following: biochemical evidence of cholestasis with elevated ALP for at least 6 months; AMA titer greater than 1:40 by immunofluorescence or immunoenzymatic reactivity, or PBC-specific ANA such as anti-gp210 or anti-sp100; or histologic evidence of PBC on liver biopsy.
    • Document evaluation for other concomitant liver disease.
    Documentation Required

    Prior Treatment Response

    Document that the member had an inadequate response to a qualifying antipruritic therapy before requesting Lynavoy. A documented contraindication, adverse effect, or intolerance may satisfy the prior-treatment requirement.

    • Identify the prior therapy, dose, duration or relevant treatment history, and response.
    • Qualifying therapies include cholestyramine/colestipol, naltrexone, rifampin, and sertraline.
    • Describe the persistent cholestatic pruritus and its impact on daily life and sleep.
    Documentation Required

    Baseline ALP and Livdelzi Documentation

    Submit the serum ALP level obtained before initiation of Lynavoy. When the serum ALP level is elevated, also submit documentation of inadequate response to Livdelzi, including any applicable contraindication, adverse effect, or intolerance.

    • Pre-initiation serum ALP is required for the requested drug.
    • Livdelzi response documentation is required when serum ALP is elevated.
    Documentation Required

    Combination Therapy Documentation

    For requests to use Lynavoy with Iqirvo or Livdelzi, document that Livdelzi monotherapy was inadequate, not tolerated, or contraindicated. The same documentation is required for applicable continuation requests.

    • Combination therapy applies to treatment of PBC and PBC-associated cholestatic pruritus.
    • Document inadequate response, intolerance, or contraindication to Livdelzi monotherapy.
    Documentation Required

    Continuation Documentation

    For continuation requests, document clinical benefit from Lynavoy and provide the initial authorization criteria documentation when Neighborhood has not previously approved the drug.

    • Clinical benefit may include improvement in pruritus.
    • Confirm ongoing hepatologist or gastroenterologist prescribing or consultation.
    • Confirm that no hepatic decompensation has developed or occurred.
    • For combination therapy, provide the required Livdelzi monotherapy response, intolerance, or contraindication documentation.
    Denial Risk

    Unapproved Indication

    Requests for Lynavoy for indications other than cholestatic pruritus associated with PBC in adults are considered experimental or investigational and are not medically necessary.

    • The FDA-approved indication is treatment of cholestatic pruritus associated with primary biliary cholangitis in adult patients.
    Denial Risk

    Hepatic Decompensation

    Coverage may be denied when the member has decompensated cirrhosis or a prior or active hepatic decompensated event.

    • Relevant events include variceal hemorrhage, ascites, and hepatic encephalopathy.
    • For continuation, deny or do not authorize when the member develops decompensated cirrhosis or experiences a hepatic decompensated event.
    Denial Risk

    Concomitant IBAT Inhibitor Use

    Lynavoy must not be used concomitantly with another ileal bile acid transporter (IBAT) inhibitor.

    • Do not use with Bylvay (odevixibat), Livmarli (maralixibat), or another IBAT inhibitor.
    • Confirm the member will not receive concurrent IBAT inhibitor therapy for both initial and continuation requests.
    Step Therapy

    Insufficient Prior Treatment History

    Initial approval requires documented qualifying prior-treatment history and response. Submit the prior therapy and evidence of inadequate response, or documentation of a contraindication, adverse effect, or intolerance, before requesting Lynavoy.

    • Qualifying prior therapies are cholestyramine/colestipol, naltrexone, rifampin, and sertraline.
    • When serum ALP is elevated, also document inadequate response, contraindication, adverse effect, or intolerance to Livdelzi.
    • For applicable combination therapy, document inadequate response, intolerance, or contraindication to Livdelzi monotherapy.
    >1:40 by immunofluorescence or immunoenzymatic reactivity
  6. Histologic evidence of PBC on liver biopsy, such as nonsuppurative inflammation and destruction of interlobular and septal bile ducts.
  7. The medication is prescribed by or in consultation with a hepatologist or gastroenterologist.
  8. The member does not have decompensated cirrhosis or prior or active hepatic decompensated events, including variceal hemorrhage, ascites, or hepatic encephalopathy.
  9. The member has been evaluated for other concomitant liver disease.
  10. The member has moderate to severe pruritus associated with PBC that impacts daily life and sleep.
  11. Prior antipruritic therapy — at least 1 therapy

    • Inadequate treatment response to cholestyramine or colestipol 4 g/dose up to 16 g/day.
    • Inadequate treatment response to naltrexone 50 mg daily.
    • Inadequate treatment response to rifampin 150 mg to 300 mg twice daily.
    • Inadequate treatment response to sertraline 75 mg to 100 mg once daily.
  12. Laboratory and sequencing requirements

    • The serum ALP level obtained before initiation of Lynavoy is documented.
    • If the member has an elevated serum ALP level, the member has experienced an inadequate treatment response to Livdelzi; any contraindication, adverse effect, and/or intolerance must be documented.
  13. Combination and concomitant-use requirements

    • If Lynavoy is requested in combination with Iqirvo or Livdelzi, the member has a documented inadequate response, intolerance, or contraindication to Livdelzi monotherapy for the treatment of PBC and associated cholestatic pruritus.
    • The member will not use Lynavoy concomitantly with another ileal bile acid transporter (IBAT) inhibitor, including Bylvay or Livmarli.
  14. The member has not developed decompensated cirrhosis or experienced a hepatic decompensated event, including variceal hemorrhage, ascites, or hepatic encephalopathy.
  15. Combination and concomitant-use requirements

    • If Lynavoy is requested in combination with Iqirvo or Livdelzi, the member has a documented inadequate response, intolerance, or contraindication to Livdelzi monotherapy for the treatment of PBC and associated cholestatic pruritus.
    • The member will not use Lynavoy concomitantly with another ileal bile acid transporter (IBAT) inhibitor, including Bylvay or Livmarli.